CompletedNCT00250575
Clozapine for treatment-resistant schizophrenia over 24 weeks
About this title
A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia
Read the official source — NCT00250575This study evaluated the safety and effectiveness of Clozapine for people with schizophrenia.
Medication studyAges 18–64Japan
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Clozapine for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Chiba and 7 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 43
- Sponsor
- Novartis
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Japan
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT00250575
- Official title
Show the full official title
A 24-week, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia
Get this study by email
Recruitment & locations
CompletedChiba · Fukuoka · Ishikawa
5 more locations
- Osaka
- Saga
- Tokyo
- Toyama
- Yamanashi
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Clozapine for people with schizophrenia.
Who is behind this study?
The study sponsor is Novartis.
Did this study involve medication?
Yes. The study involved medication, including Clozapine.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
